Filing Details

Accession Number:
0001062993-22-016556
Form Type:
4
Zero Holdings:
No
Publication Time:
2022-07-20 16:05:45
Reporting Period:
2022-07-18
Accepted Time:
2022-07-20 16:05:45
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1621443 Zynerba Pharmaceuticals Inc. ZYNE () 4
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1327442 E James Fickenscher C/O Zynerba Pharmaceuticals, Inc.
80 W. Lancaster Avenue, Suite 300
Devon PA 19333
Chief Financial Officer No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2022-07-18 20,800 $0.00 178,518 No 4 A Direct
Common Stock Disposition 2022-07-19 6,013 $1.10 172,505 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 A Direct
No 4 S Direct
Footnotes
  1. On July 18, 2022, the Compensation Committee of the Board of Directors of the Company determined that performance-vesting criteria were met with regard to 20,800 performance-based restricted stock awards granted in a prior year.
  2. This transaction represents shares required to be sold by the Reporting Person to satisfy tax obligations and certain equity plan administrator fees in connection with the vesting of shares of restricted stock. This sale was mandated by the equity plan administrator and does not represent a discretionary trade by the Reporting Person.